Active Ingredient History
Palonosetron (INN, trade name Aloxi) is a 5-HT3 antagonist used in the prevention and treatment of postoperative and chemotherapy-induced nausea and vomiting (PONV and CINV). Palonosetron is a 5-HT3 receptor antagonist with a strong binding affinity for this receptor and little or no affinity for other receptors. Cancer chemotherapy may be associated with a high incidence of nausea and vomiting, particularly when certain agents, such as cisplatin, are used. 5-HT3 receptors are located on the nerve terminals of the vagus in the periphery and centrally in the chemoreceptor trigger zone of the area postrema. It is thought that chemotherapeutic agents produce nausea and vomiting by releasing serotonin from the enterochromaffin cells of the small intestine and that the released serotonin then activates 5-HT3 receptors located on vagal afferents to initiate the vomiting reflex. Postoperative nausea and vomiting is influenced by multiple patients, surgical and anesthesia-related factors and is triggered by the release of 5-HT in a cascade of neuronal events involving both the central nervous system and the gastrointestinal tract. The 5-HT3 receptor has been demonstrated to selectively participate in the emetic response. The most common adverse effects are a headache, which occurs in 4–11% of patients, and constipation in up to 6% of patients. In less than 1% of patients, other gastrointestinal disorders occur, as well as sleeplessness, first- and second-degree atrioventricular block, muscle pain and shortness of breath. Palonosetron is similarly well tolerated as other sections, and slightly less than placebo. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Vomiting (approved 2003)
Anesthesia (Phase 4)
Anesthesia, General (Phase 3)
Antiemetics (Phase 4)
Antineoplastic Agents (Phase 2/Phase 3)
Anus Neoplasms (Phase 2)
Appendix (Phase 2)
Bile Duct Neoplasms (Phase 2)
Brain Neoplasms (Phase 2)
Breast Neoplasms (Phase 4)
Colorectal Neoplasms (Phase 2)
Drug Therapy (Phase 2)
Gallbladder Neoplasms (Phase 2)
Gastrointestinal Neoplasms (Phase 2)
Glioma (Phase 2)
Hamartoma (Phase 2)
Healthy Volunteers (Phase 1)
Intestinal Neoplasms (Phase 3)
Laparoscopy (Phase 3)
Leukemia (Phase 4)
Leukemia, Myeloid, Acute (Phase 2)
Liver Neoplasms (Phase 2)
Lung Neoplasms (Phase 2)
Lymphoma (Phase 4)
Lymphoma, Non-Hodgkin (Phase 2)
Melanoma (Phase 1/Phase 2)
Multiple Myeloma (Phase 2)
Nausea (Phase 4)
Neoplasms (Phase 4)
Neoplasms, Germ Cell and Embryonal (Phase 2)
Pain (Phase 4)
Palonosetron (Phase 4)
Pancreatic Neoplasms (Phase 2)
Pediatrics (Phase 3)
Postoperative Nausea and Vomiting (Phase 4)
Quality of Life (Phase 2/Phase 3)
Reperfusion Injury (Phase 2)
Scoliosis (Phase 4)
Sleep (Phase 3)
Stomach Neoplasms (Phase 2)
Strabismus (Phase 3)
Terminally Ill (Phase 2)
Therapeutic Uses (Phase 3)
Vomiting (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
